10 Stocks Take A Shocking Nosedive

Ten companies ended Wednesday’s trading with hefty losses as investors repositioned portfolios to mitigate risks from any potential macroeconomic developments amid the Juneteenth holiday.

Trading was in line with Wall Street’s lagged performance, with the tech-heavy Nasdaq the only finisher in the green, rising by 0.13 percent. The Dow Jones and the S&P 500 dropped by 0.10 percent and 0.03 percent, respectively.

In this article, let us explore the 10 worst-performing stocks alongside the reasons behind their drop.

To come up with the list, we considered only the stocks with at least $2 billion in market capitalization and over 5 million in trading volume.

10. Transocean Ltd. (NYSE:RIG)

Transocean dropped by 3.74 percent on Wednesday to close at $3.09 apiece as investors unloaded portfolios over the lack of fresh developments to boost buying.

Wednesday’s share price marked its third straight day of decline, suggesting that investors have already priced in earlier news that it secured another $100 million contract with existing client, Equinor ASA.

Under the agreement, Transocean Ltd. (NYSE:RIG) will drill two more wells for Equinor ASA at the Spitsbergen rig in Norway as part of the latter’s drilling extension option.

The program is expected to kick off in the first quarter of 2026 in direct continuation of the rig’s current program.

The additional work followed their original three-well program on the Norwegian Continental Shelf (NCS), which was procured in 2024.

Transocean Ltd.’s (NYSE:RIG) Spitsbergen rig was built in 2010 as a sixth-generation dual-derrick winterized semi-submersible rig, which is capable of drilling high-pressure and high-temperature formations.

9. ADMA Biologics, Inc. (NASDAQ:ADMA)

ADMA Biologics saw its share prices decline by 4.02 percent on Wednesday to finish at $18.13 apiece, as investors parked funds amid the lack of fresh catalysts to spark buying.

Wednesday’s drop marked the company’s fifth straight session in the red territory, trading lower in line with its president and CEO’s disposition of shares in the company.

According to a regulatory filing, ADMA Biologics, Inc. (NASDAQ:ADMA) President and CEO Adam Grossman sold 21,000 ADMA shares at a price of $20.81 apiece on June 16 for a total value of $437,010.

On the same day, he acquired 15,000 shares at a price of $5.4 apiece for a total of $81,000.

ADMA Biologics, Inc. (NASDAQ:ADMA) said that the transaction was in line with the Rule 10b5-1 trading plan entered into between Grossman and Fidelity Brokerage Services LLC.